Crumbling stairs, bed bugs: Inside NY's adult care facilities deemed unsafe in audit
The unaddressed health and safety risks at adult care facilities stemmed from the fact New York's Health Department at times "failed to conduct timely inspections and often lacked documentation to show critical problems were corrected," according to the state Comptroller's Office report.
Revelations surrounding the newly reported adult care facility inspection backlogs and failures came after USA TODAY Network-New York revealed state health officials failed to properly inspect nursing homes during the pandemic.
State health officials failed to complete adult care facility inspections within the required 12- to 18-month timeframe at 70% of the 30 sampled facilities, with some delayed by as much as five years, state auditors reported.
Three of the state's four regional oversight offices had inspection backlogs — New York City, Long Island and Western New York — while Central New York had no backlog.
Auditors conducted site visits at 20 of the sampled adult care facilities across the state and found a range of serious health and safety issues, including:
Crumbling stairs and walkways.
Dishwashers that didn't reach safe temperatures.
Refrigerators that weren't cold enough.
A lack of regular fire drills.
Auditors also found additional unresolved problems at adult care facilities, including:
A half-empty vodka bottle in a medical room and marijuana paraphernalia in an administrator's office.
Expired medication present four years after a prior citation.
Staff still uncertified in basic first aid more than 13 months after being cited.
Health officials also failed to document whether facilities corrected violations identified in prior inspections. Of the 89 violations reviewed in 30 inspection reports, auditors found no evidence health officials took corrective action. At 18 of 20 facilities visited, problems cited in earlier inspection reports were not fixed.
Investigation: NY vowed to improve nursing homes after COVID. The pandemic made things worse. Here's how
At the same time, health officials received 7,440 adult care facility complaints and completed 6,498 complaint investigations from 2018 through 2023.
Still, health officials failed to fully investigate some complaints or adequately document its investigations, auditors found, noting in a sample of 130 complaints, 18% of allegations had no evidence they were investigated.
Adult care facilities are primarily home to the elderly who can no longer live independently, but do not require the care of a nursing home. These facilities provide housing, meals and personal care for individuals who need help with daily activities, auditors noted.
As of 2023, there were 534 adult care facilities operating in New York, serving 37,547 residents, the report added.
More: Unsafe care to lawmaking missteps: Why we keep reporting on NY nursing home failures
The audit reviewed health officials' oversight of these facilities from January 2018 to October 2024. Health and safety issues at facilities can include, but are not limited to, inadequate staffing, call bells not functioning, no clear emergency shelter plans or the presence of mold, mice or bed bugs.
In response to the audit findings, health officials acknowledged delays in inspections and correcting violations, citing staffing shortages and the COVID-19 pandemic as major challenges. Health officials said they have increased hiring, improved tracking systems and created a quality assurance committee to strengthen oversight moving forward.
Addressing the stakes of New York's failed oversight of adult care facilities, state Comptroller Thomas DiNapoli asserted proper inspections "ensure residents are not left in unsafe or unsanitary conditions."
"If the state Department of Health isn't conducting timely inspections or following up to make sure violations are corrected, then vulnerable residents could be left at risk,' he added.
David Robinson is a veteran health reporter for the USA TODAY Network's New York State Team. Reach him at Drobinson@lohud.com.
This article originally appeared on Rockland/Westchester Journal News: NY's adult care facilities deemed unsafe in state audit

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
29 minutes ago
- The Hill
180 shots were fired in CDC attack in Atlanta
A lone gunman fired 180 shots at the Atlanta Centers for Disease Control and Prevention (CDC) headquarters on Friday, with bullets piercing about 150 windows, the Associated Press reported, citing internal reports. An array of buildings was damaged, including one where CDC Director Susan Monarez's office is housed. Police identified Patrick Joseph White as the gunman and said he opened fire on the campus following claims that the COVID-19 vaccine made him severely depressed and suicidal, AP reported. One police officer was killed during the incident; White was also fatally shot. Investigators are still working to uncover whether he succumbed to self-inflicted bullet wounds or if he was struck by law enforcement's gun fire. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. visited the site Monday, touring the area with HHS Deputy Secretary Jim O'Neill and Monarez, according to a press release from the department. 'We know how shaken our public health colleagues feel today. No one should face violence while working to protect the health of others,' Kennedy wrote in a post on X, following the shooting. 'We are actively supporting CDC staff on the ground and across the agency. Public health workers show up every day with purpose — even in moments of grief and uncertainty,' he added. 'We honor their service. We stand with them.' However, some are blaming Kennedy, a former anti-vaccine advocate, for the attack. 'When your own leadership peddles falsehoods, it doesn't just erode the public trust. It creates the conditions for the kind of violence that we saw on Friday,' Yolanda Jacobs, president of AFGE Local 2883, said in a statement. The labor union issued an open letter containing demands to depoliticize the agency, increase security presence and create more telework opportunities in the wake of the violent incident.
Yahoo
34 minutes ago
- Yahoo
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034
The outlook for the gastric cancer treatment market appears favorable, fueled by progress in targeted therapies and immunotherapies. Traditionally, platinum-based chemotherapy has served as the primary treatment for early-stage gastric cancer, underscoring the demand for more effective alternatives. New York, USA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight The outlook for the gastric cancer treatment market appears favorable, fueled by progress in targeted therapies and immunotherapies. Traditionally, platinum-based chemotherapy has served as the primary treatment for early-stage gastric cancer, underscoring the demand for more effective alternatives. DelveInsight's Gastric Cancer Market Insights report includes a comprehensive understanding of current treatment practices, emerging gastric cancer drugs, market share of individual therapies, and current and forecasted gastric cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Gastric Cancer Market Report According to DelveInsight's analysis, the total gastric cancer market size is expected to grow positively by 2034. The United States accounts for the largest market size of gastric cancer, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. The total number of incident cases of gastric cancer (including GEJ) in the 7MM accounted for approximately 211K in 2024. These cases are expected to increase by 2034. Prominent companies, including Amgen, Jazz Pharmaceuticals, BeiGene, Zymeworks, AstraZeneca, ALX Oncology, Pfizer, KLUS Pharma, Enliven Therapeutics, Ambrx, NovoCodex, and others, are actively working on innovative gastric cancer drugs. Some of the key gastric cancer therapies in the pipeline include Bemarituzumab, ZIIHERA (zanidatamab), Rilvegostomig, AZD0901, Evorpacept (ALX148), TUKYSA (tucatinib), A166 (Trastuzumab botidotin), ELVN-002, ARX788, and others. These novel gastric cancer therapies are anticipated to enter the gastric cancer market in the forecast period and are expected to change the market. Discover which gastric cancer medications are expected to grab the market share @ Gastric Cancer Market Report Gastric Cancer Market Dynamics The gastric cancer market dynamics are anticipated to change in the coming years. HER2-targeted therapies such as HERCEPTIN, ENHERTU, and the anti-PD1 therapy KEYTRUDA offer more precise treatment options that improve efficacy while minimizing side effects compared to traditional chemotherapy. ENHERTU, developed by Daiichi Sankyo and AstraZeneca, is expanding into the first-line (1L) treatment setting, which is expected to boost its patient share and drive market growth. Additionally, there is growing research interest in combining next-generation HER2 inhibitors or bispecific antibodies with immune checkpoint inhibitors (ICIs), presenting a significant opportunity to enhance treatment outcomes and improve patient survival. Overall, the gastric cancer market is poised for expansion, driven by rising incidence rates, an aging population, and continued advancements in treatment approaches, encouraging further investment in research and development. Furthermore, many potential therapies are being investigated for the treatment of gastric cancer, and it is safe to predict that the treatment space will significantly impact the gastric cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the gastric cancer market in the 7MM. However, several factors may impede the growth of the gastric cancer market. HER2+ gastric cancer is an aggressive form of the disease with a significantly high mortality rate and poor prognosis, driven by low screening rates, a high incidence of refractory or relapsed tumors, and an older patient population; furthermore, the complex tumor biology, including intratumoral heterogeneity, poses challenges for effective treatment and limits current therapies, while the propensity for developing resistance to targeted treatments necessitates ongoing development of next-generation agents, thereby increasing R&D costs. Moreover, gastric cancer treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the gastric cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the gastric cancer market Cancer Treatment Market Gastrectomy is the mainstay of treatment for early-stage gastric or gastroesophageal junction (GEJ) cancers and can potentially cure patients; however, the survival rate for those with advanced resectable disease remains poor despite the advent of perioperative chemotherapy or adjuvant chemoradiation strategies. The choice of treatment depends on several factors, including tumor size, location, and the patient's overall health. In metastatic settings, HER2, a receptor overexpressed or amplified in 6–36% of gastric cancer patients, has emerged as a key therapeutic target. Targeted agents such as HERCEPTIN (trastuzumab), which inhibits HER2-mediated tumor proliferation, and immune checkpoint inhibitors like KEYTRUDA (pembrolizumab), which blocks PD-1/PD-L1 interaction to enhance antitumor immune response, have received FDA approval. More recently, agents like ENHERTU (Daiichi Sankyo) and AIDIXI (Remegen Biosciences) have been approved for second- and third-line treatment, reflecting the growing role of precision therapies in managing advanced gastric cancer. Learn more about the gastric cancer treatment options @ Gastric Cancer Treatment Guidelines Gastric Cancer Emerging Drugs and Companies Pharmaceutical companies developing therapies for treating gastric cancer include Amgen (Bemarituzumab), ALX Oncology (Evorpacept), Jazz Pharmaceuticals, BeiGene, and Zymeworks (ZIIHERA), Enliven Therapeutics (ELVN-002), Ambrx and NovoCodex (ARX788), AstraZeneca (Rilvegostomig and AZD0901), KLUS Pharma (A166), Pfizer (TUKYSA), and others with their candidates in different stages of clinical development. Bemarituzumab is a monoclonal antibody targeting the fibroblast growth factor receptor 2b (FGFR2b) and is under investigation for the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. In April 2021, Amgen announced that the U.S. FDA had granted bemarituzumab breakthrough therapy designation. The drug is also undergoing Phase I and Phase II clinical trials in combination with other treatments for these cancers. According to Amgen's May 2025 presentation, the company plans to release data from the Phase III FORTITUDE-101 trial, evaluating bemarituzumab as a first-line treatment for gastric cancer, in Q2 2025. Another Phase III trial, FORTITUDE-102, is expected to report results in the latter half of 2025. ZIIHERA, a bispecific HER2-directed antibody that targets two external HER2 binding sites, received FDA accelerated approval in November 2024 for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), based on an FDA-approved diagnostic. The drug is currently in Phase III development for treating HER2-positive unresectable, locally advanced, or metastatic gastroesophageal adenocarcinoma. Zanidatamab, being jointly developed by Jazz Pharmaceuticals and BeiGene under a license from Zymeworks, the original developer, is also progressing in the gastroesophageal adenocarcinoma (GEA) space. Jazz is exploring zanidatamab's potential use in the neoadjuvant and adjuvant settings for GEA. The pivotal Phase III HERIZON-GEA-01 trial (NCT05152147), evaluating zanidatamab in combination with chemotherapy—with or without tislelizumab—as a first-line therapy for HER2-expressing metastatic GEA, is expected to deliver top-line data in Q2 2025. As per a company presentation from January 2025, Jazz Pharmaceuticals anticipates submitting a supplemental Biologics License Application (sBLA) for zanidatamab later in 2025, aiming for approval in the first-line GEA setting. The anticipated launch of these emerging gastric cancer therapies are poised to transform the gastric cancer market landscape in the coming years. As these cutting-edge gastric cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the gastric cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for gastric cancer, visit @ Gastric Cancer Management Recent Developments in the Gastric Cancer Market In February 2025, AstraZeneca expects the first patient dosing of ENHERTU (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or metastatic gastric cancer or GEJ adenocarcinoma to begin in Q1 2025, with data anticipated to be available after 2026. In January 2025, ALX Oncology presented positive updated data from the ASPEN-06 Phase II clinical trial at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrating that the company's investigational CD47-blocker, evorpacept, produces a durable clinical response and exhibits a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric cancer or GEJ cancer. Gastric Cancer Overview Gastric cancer develops when malignant cells form in the stomach lining. The stomach wall consists of five layers: the mucosa, submucosa, muscularis propria, subserosa, and serosa. The tumour's location and the depth of layer involvement are critical in determining the cancer's stage, which influences both treatment strategies and prognosis. As the cancer progresses from the mucosa to deeper layers, it becomes more advanced, requiring more intensive therapy. To detect gastric cancer, physicians typically assess the patient's medical and family history, conduct a physical examination, and carry out blood and stool tests to check for anemia or internal bleeding. Core diagnostic methods include an upper endoscopy with biopsy, using a thin, illuminated tube to inspect the esophagus, stomach, and duodenum, and barium swallow X-rays for imaging the digestive tract. Further staging is supported by advanced imaging techniques like CT scans, endoscopic ultrasound, PET-CT scans, and MRI, which help shape the treatment plan. The gastric cancer report outlines the disease's underlying biology, diagnostic methods, and a real-life patient case study that traces the journey from initial symptoms to diagnosis and complete treatment. Gastric Cancer Epidemiology Segmentation The gastric cancer epidemiology section provides insights into the historical and current gastric cancer patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The gastric cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of Gastric Cancer Stage-specific Cases of Gastric Cancer Gender-specific Cases of Gastric Cancer Biomarker-specific Cases of Gastric Cancer Total Treatable Cases of Gastric Cancer Download the report to understand which factors are driving gastric cancer epidemiology trends @ Gastric Cancer Treatment Algorithm Gastric Cancer Report Metrics Details Study Period 2020–2034 Gastric Cancer Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Gastric Cancer Companies Amgen, Jazz Pharmaceuticals, BeiGene, Zymeworks, AstraZeneca, ALX Oncology, Pfizer, KLUS Pharma, Enliven Therapeutics, Ambrx, NovoCodex, and others Key Gastric Cancer Therapies Bemarituzumab, ZIIHERA (zanidatamab), Rilvegostomig, AZD0901, Evorpacept (ALX148), TUKYSA (tucatinib), A166 (Trastuzumab botidotin), ELVN-002, ARX788, KEYTRUDA, ENHERTU, OPDIVO, CYRAMZA, and others Scope of the Gastric Cancer Market Report Gastric Cancer Therapeutic Assessment: Gastric Cancer current marketed and emerging therapies Gastric Cancer Market Dynamics: Conjoint Analysis of Emerging Gastric Cancer Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Gastric Cancer Market Access and Reimbursement Discover more about gastric cancer drugs in development @ Gastric Cancer Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Methodology 6 Gastric Cancer: Market Overview at a Glance 6.1 Total Market Share (%) Distribution of Gastric Cancer by Therapies in 2020 6.2 Total Market Share (%) Distribution of Gastric Cancer by Therapies in 2034 7 Disease Background and Overview: Gastric Cancer 7.1 Introduction 7.2 Risk Factors 7.3 Symptoms 7.4 Pathophysiology and disease pathways 7.5 Diagnostic Tests: Biomarker assays 8 Treatment and Guidelines 8.1 Current Treatment Landscape 9 Epidemiology and Patient Population 9.1 Key Findings 9.2 Assumptions and Rationale 9.3 Total Incident Cases of Gastric Cancer in the 7MM 9.4 The United States 9.4.1 Total Incident Cases of Gastric Cancer in the United States 9.4.2 Stage-specific Cases of Gastric Cancer in the United States 9.4.3 Gender-specific Cases of Gastric Cancer in the United States 9.4.4 Biomarker-specific Cases of Gastric Cancer in the United States 9.4.5 Total Treatable Cases of Gastric Cancer in the United States 9.5 EU4 and the UK 9.6 Japan 10 Patient Journey 11 Marketed Drugs 11.1 Key Competitors 11.2 ENHERTU (Fam-Trastuzumab Deruxtecan-nxki): AstraZeneca/Daiichi Sankyo 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Development Activities 11.2.4 Clinical Development 11.2.4.1 Clinical Trial Information 11.2.5 Safety and Efficacy 11.2.6 Analyst Views 11.3 OPDIVO (nivolumab): Bristol-Myers Squibb List to be continued in the report… 12 Emerging Therapies 12.1 Key Competitors 12.2 Bemarituzumab: Amgen 12.2.1 Product Description 12.2.2 Other Developmental Activities 12.2.3 Clinical Development 12.2.3.1 Clinical Trial Information 12.2.4 Safety and Efficacy 12.2.5 Analyst Views 12.3 ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks List to be continued in the report… 13 Gastric Cancer: Market Size 13.1 Key Findings 13.2 Market Outlook 13.3 Conjoint Analysis 13.4 Key Market Forecast Assumptions 13.4.1 Cost Assumptions and Rebates 13.4.2 Pricing Trends 13.4.3 Analogue Assessment 13.4.4 Launch Year and Therapy Uptakes 13.5 Total Market Size of Gastric Cancer in the 7MM 13.6 The United States 13.6.1 Total Market Size of Gastric Cancer in the United States 13.6.2 Total Market Size of Gastric Cancer by Therapies in the United States 13.7 EU4 and the UK 13.7.1 Total Market Size of Gastric Cancer in EU4 and the UK 13.7.2 Total Market Size of Gastric Cancer by Therapies in EU4 and the UK 13.8 Japan 13.8.1 Total Market Size of Gastric Cancer in Japan 13.8.2 Total Market Size of Gastric Cancer by Therapies in Japan 14 Unmet Needs 15 SWOT Analysis 16 KOL Views 17 Market Access and Reimbursement 18 Bibliography 19 Report Methodology Related Reports Gastric Cancer Pipeline Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gastric cancer companies, including EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, among others. HER2+ Gastric Cancer Market HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HER2+ gastric cancer companies including AstraZeneca, Daiichi Sankyo, Merck, Jazz Pharmaceuticals, BeiGene, Zymeworks, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, among others. HER2+ Gastric Cancer Pipeline HER2+ Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2+ gastric cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others. Metastatic Prostate Cancer Market Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others. HER2+ Gastric Cancer Epidemiology HER2+ Gastric Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the HER2+ gastric cancer epidemiology trends. Gastric Cancer Epidemiology Gastric Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the gastric cancer epidemiology trends. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter CONTACT: Contact Us Shruti Thakur info@ +14699457679 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Politico
an hour ago
- Politico
CDC workers question safety after fatal shooting
With help from Erin Schumaker Driving the Day STAFFERS TRAUMATIZED — Centers for Disease Control and Prevention employees are afraid to return to work after Friday's deadly shooting at the agency's Atlanta headquarters, three agency staffers said. 'Even the ones who weren't in lockdown for seven hours and are ridiculously traumatized … even everybody else, I'm getting questions about 'Are our windows bulletproof? And what about the areas without cell reception?'' one of the staffers said. They were granted anonymity for fear of retribution. Some employees say HHS Secretary Robert F. Kennedy Jr.'s spread of vaccine misinformation might have villainized the CDC in the eyes of some, Sophie reports. Some media outlets have reported that the suspected shooter, 30-year-old Patrick White, believed that the Covid-19 vaccine made him sick. White died at the scene, authorities said. 'I think most of us would very much like the next message we hear from him to begin with 'I hereby resign,'' a fourth staffer told POLITICO in a text. 'The secretary is being widely (and accurately) blamed for spreading disinformation about vaccines that helped poison the mind of a disturbed individual.' No CDC employees were injured. DeKalb County Police Officer David Rose was shot and killed while responding to the incident. Key context: The shooting comes amid an already tumultuous time for CDC staff. In April, the administration sent termination notices to hundreds of CDC employees, and the Trump administration has proposed slashing the agency's budget by roughly half. HHS spokesperson Andrew Nixon said in a statement that Kennedy 'unequivocally condemned the horrific attack and remains fully committed to ensuring the safety and well-being of CDC employees.' The latest: Kennedy visited the agency's headquarters Monday to survey the damage, HHS said. He was joined by newly confirmed CDC Director Susan Monarez. One of the staffers said employees are closely watching how Monarez, who was sworn in late last month, will speak to staff about the shooting at an agencywide meeting on Tuesday. 'I hope that she is using her voice, internally and frankly externally, as our brand new leader,' the staffer said. What's next: The CDC has extended telework for a week to everyone who works from CDC campuses in Atlanta, the first staffer said. It's still unclear when employees will be expected to return to the agency's Edward R. Roybal campus, which sustained extensive damage. Employees at other campuses can return to work today or continue to work remotely for the rest of the week if they choose to, a second staffer based in a campus outside Atlanta confirmed to POLITICO. 'The campus is not going to feel ready for us to come back to, and we want to make sure that it feels ready and feels safe for us to get back there at some point,' said Christa Capozzola, the agency's acting chief operating officer, on a call with agency staff Saturday. POLITICO obtained a partial recording of the call. The agency is conducting a 'full security assessment,' Monarez said on the call. WELCOME TO TUESDAY PULSE. Actress Cheryl Hines, the wife of HHS Secretary Robert F. Kennedy Jr., is releasing a new memoir, titled 'Unscripted.' Send your tips, scoops and feedback to khooper@ and sgardner@ and follow along @kelhoops and @sophie_gardnerj. Make America Healthy Again MAHA REPORT HEADS TO TRUMP — Health Secretary Robert F. Kennedy Jr.'s long-awaited strategy for 'making children healthy again' is expected to be delivered to President Donald Trump today but not yet made available to the public, POLITICO's David Lim, Marcia Brown and Megan Messerly report. Today is the Make America Healthy Again Commission's deadline — as required through executive order — to present the report to Trump. But White House spokesperson Kush Desai said that the group will take more time to coordinate officials' schedules to release the report to the public. Why it matters: The upcoming MAHA policy recommendations are expected to suggest a restructuring of the government's response to childhood chronic diseases and will have wide-ranging implications for food, farm and health policy. Background: Industry groups and Kennedy devotees have lobbied heavily to affect what's in the closely watched document and had expected its public release would coincide with the executive order's deadline for sending the strategy to Trump, as was the case with an earlier report assessing the health risks facing children in May. The White House has been hosting preview meetings with stakeholders ahead of the August report's release, according to a person familiar with the timing who was granted anonymity to discuss the conversations. Eye on Insurers LONG-TERM SERVICES — Fewer Medicare Advantage beneficiaries were enrolled in plans offering long-term support services in 2025 than in 2019, according to a new study published in JAMA Network Open. The availability of the long-term support benefits, which include care in nursing homes and assisted-living facilities, within the privately run alternative to Medicare has largely remained unchanged over that period, according to the study. But the share of Medicare Advantage beneficiaries enrolled in plans with LTSS benefits has decreased 14 percentage points, report the paper's researchers from Harvard Medical School. 'Taken together, these results suggest that with the increase in MA enrollment over time, access to LTSS within MA has potentially become more limited,' they wrote. Why it matters: In 2018, more than 18 million people needed long-term services and support, with 56 percent of those people over age 65. But private health insurance doesn't generally cover LTSS, and Medicare's coverage is limited. Background: Because of a 2018 HHS policy, Medicare Advantage plans began offering long-term supplemental benefits like in-home support services, caregiver support and home-based palliative care. Still, plan offerings within the private program can be scarce, and the level of benefits offered can be limited. In 2025, the share of Medicare Advantage plans offering any LTSS was 12.3 percent, compared with 12.9 percent in 2019 when the rule went into effect, according to the study. Key context: The slightly more limited availability of Medicare Advantage plans with LTSS benefits in 2025 could be partly attributed to some plans ceasing to exist, as health insurers in recent years have increasingly exited markets where plans were unprofitable, according to the study. Another factor could be that insurers view offering the benefits as financially impractical because of insufficient federal funding. At the Agencies NIH DEPARTURE — The National Institutes of Health official who oversaw grant review and the groups who evaluate NIH grant applications is leaving the agency at the end of the month, Erin reports. NIH Director Jay Bhattacharya said Noni Byrnes, who directs the agency's Center for Scientific Review, is retiring from federal service after nearly 25 years at the agency. Byrnes had served as the center's director since 2019. During her time there, Byrnes, an expert in analytical chemistry, implemented frameworks and systems for evaluating quality, integrity and fairness in grant review. 'Most recently, she oversaw the HHS and NIH effort to centralize the peer review of applications and proposals for all the agency's grants, cooperative agreements, and research and development contracts,' Bhattacharya's announcement said. Byrnes' other efforts included expanding the advisory councils and pushing to diversify the pool of peer reviewers and study sections to include researchers of different races, genders, scientific backgrounds and experience. 'You don't want bureaucrats or government officials making these decisions,' Byrnes told Chemical and Engineering News in 2019, referring to the grant review process. Why it matters: The NIH's peer review process is in the midst of an overhaul. In March, the NIH said it would centralize what had previously been handled by subject matter experts at individual institutes and centers. This spring, the NIH moved to remove swaths of outside experts from advisory boards that evaluate agency research. And last week, President Donald Trump issued an executive order that increases the administration's control over research grants that the government funds. According to the order, agencies shouldn't fund research that uses race as selection criteria, denies that sex is binary or suggests that sex can be changed, encourages or subsidizes illegal immigration, compromises public safety or promotes anti-American values. The order tasks agency officials with defining those terms. What's next: The Center for Scientific Review's deputy director, Bruce Reed, will serve as the center's acting director. WHAT WE'RE READING The New Yorker's Dhruv Khullar reports on an ultra-rare disease that accelerates aging. STAT's Casey Ross, Bob Herman, Tara Bannow and Lizzy Lawrence report on the research machine that helps UnitedHealth Group protect its Medicare profits.